-
1 month ago | 
healio.com | Holly Liptak |Roger A. Goldberg |Christine Klimanskis
KOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2025, Roger A. Goldberg, MD, MBA, highlights advancements in the treatment of retinal vein occlusion. Goldberg discussed the FDA approval of Vabysmo (faricimab, Genentech) for the treatment of retinal vein occlusion (RVO) and the possible label expansion of high-dose aflibercept for the treatment of RVO in the coming year. “Retinal vein occlusion is kind of the forgotten stepchild of retinal vascular diseases,” Goldberg said.
-
2 months ago | 
healio.com | Roger A. Goldberg |Anthony DeFino |Christine Klimanskis
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA,discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors. Imaging confirms the correct diagnosis, identifies which patients will be the best responders for complement inhibitors and detects subtle signs of choroidal neovascularization, he said.
-
May 20, 2024 | 
healio.com | Roger A. Goldberg |Anthony DeFino |Eamon Dreisbach |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SEATTLE — In this Healio Video Perspective from the ARVO meeting, Roger A.
-
Mar 22, 2024 | 
evolvemeded.com | Roger A. Goldberg |A. Paul Chous |Joseph W. Sowka
Upon completion of this activity, the participant should be able to: Review advances in current treatments for diabetic eye disease and nAMD Identify patients who may benefit from advances in the treatment paradigm for retinal vascular diseases Formulate strategies to identify and resolve barriers to optimal treatment outcomes for patients with nAMD and diabetic eye disease Summarize therapies for retinal vascular diseases that are in clinical development Evolve Medical Education LLC (Evolve)...
-
Feb 9, 2024 | 
healio.com | Roger A. Goldberg |Cory Perla |Christine Klimanskis
Read more You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this expert perspective from Hawaiian Eye 2024, Roger A.
-
Feb 9, 2024 | 
healio.com | Roger A. Goldberg |Cory Perla |Christine Klimanskis
Read more You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this expert perspective from Hawaiian Eye 2024, Roger A.
-
Feb 5, 2024 | 
healio.com | Roger A. Goldberg |Anthony DeFino |Christine Klimanskis
You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024,Roger A.
-
Feb 2, 2024 | 
healio.com | Roger A. Goldberg |Anthony DeFino |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Roger A.
-
Dec 13, 2023 | 
ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig
December 13, 2023Retina experts deliberate on the role of fluorescein angiography in AMD and discuss initiation of anticomplement therapy for geographic atrophy in conjunction with anti-VEGF therapy for neovascular AMD. Arghavan Almony, MD: That was a great case. Let me step back for a second to the diagnosis. We had not 1 but 2 FAs [fluorescein angiograms] in this case. I think a lot of retina specialists are going away from FA more and more for many reasons.
-
Dec 13, 2023 | 
ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig
Arghavan Almony, MD: We’ll move to our third case. Roger, if you could. Roger Goldberg, MD: I’m pleased to be sharing a case from my good friend and colleague Nate Steinle[, MD] down in Santa Barbara, [California]. This is a patient of his whom he refers to as one of his true VIP patients. [This is] a 71-year-old [woman] with slow-onset blurred vision in both eyes. Here’s the color fundus photo of the right eye, and we see a little bit of [geographic] atrophy present and drusen.
